Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure

Type 2 diabetes mellitus affects nearly 7% of the world’s population and is a significant contributor to the development of cardiovascular disease and heart failure. Historically, the pharmacologic therapy of cardiovascular disease has centered around blood pressure control, insulin and cholesterol...

Full description

Saved in:
Bibliographic Details
Main Authors: Dana Darwish, Pooja Kumar, Khushi Urs, Siddharth Dave
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/14/12/919
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849435303048118272
author Dana Darwish
Pooja Kumar
Khushi Urs
Siddharth Dave
author_facet Dana Darwish
Pooja Kumar
Khushi Urs
Siddharth Dave
author_sort Dana Darwish
collection DOAJ
description Type 2 diabetes mellitus affects nearly 7% of the world’s population and is a significant contributor to the development of cardiovascular disease and heart failure. Historically, the pharmacologic therapy of cardiovascular disease has centered around blood pressure control, insulin and cholesterol management, the inhibition of the renin–angiotensin system, and catecholamine blockade. Recent evidence suggests that sodium–glucose cotransporter 2 (SGLT-2) inhibitors provide significant cardiovascular protection to patients with and without diabetes. The use of SGLT-2 inhibitors is associated with significant changes to serum biomarkers of cardiac function. In this narrative review, we summarize how biomarkers reflect physiologic aspects of cardiovascular function and how these are affected by the use of SGLT-2 inhibitors.
format Article
id doaj-art-7338da62b4284beaa792806bc2f3308b
institution Kabale University
issn 2073-4409
language English
publishDate 2025-06-01
publisher MDPI AG
record_format Article
series Cells
spelling doaj-art-7338da62b4284beaa792806bc2f3308b2025-08-20T03:26:20ZengMDPI AGCells2073-44092025-06-01141291910.3390/cells14120919Impact of SGLT-2 Inhibitors on Biomarkers of Heart FailureDana Darwish0Pooja Kumar1Khushi Urs2Siddharth Dave3Department of Anesthesiology and Pain Medicine, University of Texas Southwestern, Dallas, TX 75390, USASchool of Medicine, University of Texas Southwestern, Dallas, TX 75390, USAUniversity of Texas Southwestern Medical Center, Dallas, TX 75390, USADepartment of Anesthesiology and Pain Medicine, University of Texas Southwestern, Dallas, TX 75390, USAType 2 diabetes mellitus affects nearly 7% of the world’s population and is a significant contributor to the development of cardiovascular disease and heart failure. Historically, the pharmacologic therapy of cardiovascular disease has centered around blood pressure control, insulin and cholesterol management, the inhibition of the renin–angiotensin system, and catecholamine blockade. Recent evidence suggests that sodium–glucose cotransporter 2 (SGLT-2) inhibitors provide significant cardiovascular protection to patients with and without diabetes. The use of SGLT-2 inhibitors is associated with significant changes to serum biomarkers of cardiac function. In this narrative review, we summarize how biomarkers reflect physiologic aspects of cardiovascular function and how these are affected by the use of SGLT-2 inhibitors.https://www.mdpi.com/2073-4409/14/12/919SGLT-2 inhibitorsheart failurediabetes mellituscardiac biomarkers
spellingShingle Dana Darwish
Pooja Kumar
Khushi Urs
Siddharth Dave
Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
Cells
SGLT-2 inhibitors
heart failure
diabetes mellitus
cardiac biomarkers
title Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
title_full Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
title_fullStr Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
title_full_unstemmed Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
title_short Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
title_sort impact of sglt 2 inhibitors on biomarkers of heart failure
topic SGLT-2 inhibitors
heart failure
diabetes mellitus
cardiac biomarkers
url https://www.mdpi.com/2073-4409/14/12/919
work_keys_str_mv AT danadarwish impactofsglt2inhibitorsonbiomarkersofheartfailure
AT poojakumar impactofsglt2inhibitorsonbiomarkersofheartfailure
AT khushiurs impactofsglt2inhibitorsonbiomarkersofheartfailure
AT siddharthdave impactofsglt2inhibitorsonbiomarkersofheartfailure